ozekibart (INBRX-109)

May 14, 2025: Inhibrx Biosciences, Inc. (NASDAQ: INBX) reported Q1 2025 results and highlighted upcoming 2025 clinical catalysts for two ongoing programs.

For ozekibart (INBRX-109), the company expects data in unresectable or metastatic conventional chondrosarcoma from a registration-enabling Phase 2 trial in Q3 2025. It also expects initial data from a colorectal cancer expansion cohort in Q3 2025 and interim data from an Ewing sarcoma expansion cohort in 2H 2025.

For INBRX-106, initial Phase 2 data from the randomized Phase 2/3 trial in head and neck squamous cell carcinoma in combination with KEYTRUDA (pembrolizumab) are expected in Q4 2025. Interim data from the Phase 1/2 trial in checkpoint inhibitor-refractory or relapsed non-small cell lung cancer are also expected in Q4 2025.

Financially, cash and cash equivalents were $216.5 million as of March 31, 2025, versus $152.6 million at December 31, 2024, with the increase reflecting receipt of $100.0 million in gross principal in January 2025 under a loan agreement with Oxford Finance. Q1 2025 net loss was $43.3 million, compared with $78.7 million in Q1 2024.